ClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results
Rhea-AI Summary
ClearPoint Neuro (Nasdaq:CLPT) reported record 2025 results with $37.0M revenue, 18% growth, and Q4 revenue of $10.4M (34% growth). The company completed the November 2025 acquisition of IRRAS, secured $20.0M additional financing access, achieved EU MDR certification, and ended 2025 with $45.9M cash.
Management projects 2026 revenue of $52.0–$56.0M and highlighted product, commercial, and cell/gene therapy expansion initiatives.
Positive
- Full-year revenue of $37.0M, up 18% year-over-year
- Q4 revenue of $10.4M, representing 34% growth
- Completed acquisition of IRRAS expanding neurocritical care product line
- Cash and cash equivalents of $45.9M at year-end
- EU MDR certification for Navigation Software v3.0.2
- Guidance: 2026 revenue expected between $52.0M and $56.0M
Negative
- Operating expenses increased 21% to $46.9M in 2025
- Operating cash used of $23.9M during 2025
- Capital equipment and software revenue declined 18% to $3.1M
News Market Reaction – CLPT
On the day this news was published, CLPT declined 13.93%, reflecting a significant negative market reaction. Argus tracked a trough of -12.2% from its starting point during tracking. Our momentum scanner triggered 26 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $54M from the company's valuation, bringing the market cap to $332M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CLPT is up 2.22% with mixed moves across peers; BFLY shows modest upside momentum while other medical device names are flat-to-mixed, indicating a stock-specific earnings reaction.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Q3 2025 earnings | Positive | -13.3% | Reported Q3 2025 revenue growth, strong margins, and reiterated revenue guidance. |
| Aug 12 | Q2 2025 earnings | Positive | +13.1% | Record Q2 2025 revenue and new $105M note financing with reaffirmed guidance. |
| May 13 | Q1 2025 earnings | Positive | -12.5% | Record Q1 2025 revenue with strong consumables growth and maintained guidance. |
| Feb 26 | FY 2024 earnings | Positive | -17.5% | Reported record 2024 revenue, improved gross margin, and 2025 growth outlook. |
| Nov 07 | Q3 2024 earnings | Positive | -13.2% | Strong Q3 2024 revenue growth, higher device sales, and reduced cash burn. |
Earnings releases have often been followed by negative price moves despite generally strong growth updates; only one of the last five earnings reports saw a positive next-day reaction.
Over the past five earnings cycles, ClearPoint Neuro has repeatedly reported record or strong revenue growth, expanding its neurosurgery and biologics platforms while securing financing and regulatory milestones. Despite this, four of the last five earnings events (from Nov 2024 through Nov 2025) saw negative price reactions, even when guidance was reaffirmed or raised. Today’s full-year 2025 results and 2026 outlook continue that growth narrative, now incorporating the IRRAS acquisition and expanded neurosurgery offerings.
Historical Comparison
In the past five earnings releases, CLPT’s average next-day move was -8.67%, mostly selling off on strong results. Today’s 2.22% gain is modestly more constructive than that pattern.
Across recent earnings, ClearPoint has delivered sequential record revenues, expanded neurosurgery and biologics offerings, secured significant note financing, and then integrated the IRRAS acquisition. This report extends that trend with higher 2025 revenue, stable gross margins, more cash on hand, and updated 2026 revenue guidance that incorporates the broadened product portfolio.
Regulatory & Risk Context
An effective S-3 resale registration filed on 2026-01-14 covers up to 1,312,570 ClearPoint shares held by former IRRAS owners; the company itself is not selling shares and will not receive proceeds from these sales.
Market Pulse Summary
The stock dropped -13.9% in the session following this news. A negative reaction despite record $37.0M 2025 revenue and 34% Q4 growth would fit the pattern of prior earnings, which averaged a -8.67% next-day move. The market could focus on the widened $25.54M net loss and $46.9M in operating expenses even as cash rose to $45.9M. An effective resale registration for 1,312,570 shares held by former IRRAS owners may also factor into sentiment, though the company receives no proceeds.
Key Terms
eu mdr certification regulatory
ce-marked regulatory
fda clearance regulatory
form 10-k regulatory
form 10-q regulatory
notes payable financial
AI-generated analysis. Not financial advice.
Record Revenue and IRRAS Holdings Acquisition Highlight the Company's 'Fast. Forward.' Strategy
SOLANA BEACH, CA / ACCESS Newswire / March 17, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its fourth quarter and full year ended December 31, 2025.
2025 Full Year and Fourth Quarter Highlights
Reported fourth quarter revenue of
$10.4 million , including$1.2 million of IRRAflow revenue, representing34% overall growth and19% year-over-year organic growth compared with the fourth quarter of 2024;Reported revenue of
$37.0 million for the full year 2025, an overall increase of18% and14% increase in organic growth over 2024 and signifying the eleventh consecutive year of growth;Completed the acquisition of IRRAS Holdings, Inc., in November 2025 expanding the Company's portfolio into neurocritical care, and allowing an expanded set of solutions spanning functional neurosurgery, neurocritical care, and intracranial drug delivery;
In conjunction with the IRRAS acquisition, entered into an agreement to access an additional
$20.0 million in funding under the existing note financing arrangement with Oberland Capital;Received EU MDR Certification for ClearPoint Navigation Software Version 3.0.2, expanding the Company's latest operating room navigation platform to EU customers;
Completed initial development and showcased a prototype of the Company's proprietary robotic neuro-navigation system at the 75th Annual Congress of Neurological Surgeons in Los Angeles in October 2025; and
Reported cash and cash equivalents totaling
$45.9 million as of December 31, 2025.
"Our Company ended 2025 on a high note with the strongest financial quarter of the year, a newly acquired and commercialized neurocritical care product line, and a genuine excitement regarding our 2026 opportunities," commented Joe Burnett, President and CEO at ClearPoint Neuro. "We have invested more than
"As we look ahead, we have now entered the next two phases of our growth strategy:"
"The first phase, which we call "Fast. Forward." is to penetrate an existing
"The second phase, which we call "Essential. Everywhere." is to build a new market that does not yet exist for commercial cell and gene therapy delivery. This is a market in which we believe that the unique ClearPoint Neuro ecosystem will play an essential role. This ecosystem will include brain segmentation tools, predictive drug-delivery modeling, pre-planning and navigation software, frame and robotic delivery options, drug loading and mechanized infusion technologies, an array of cell and gene therapy routes-of-administration, and post procedure quality confirmation software to meticulously track proper delivery. All of these workflow steps will be supported by our talented team of clinical specialists and scientists who will be there in the room, assisting our partners when these new-to-world therapies are first commercialized."
"For 2026, we now expect revenues to be in the range of
Business Outlook
The Company estimates revenue in 2026 to be between
Financial Results - Year Ended December 31, 2025
Total revenue was
Biologics and drug delivery revenue, which include sales of disposable products and services related to customer-sponsored preclinical and clinical trials utilizing our products, increased
Neurosurgery navigation and therapy revenue, which primarily consists of disposable product commercial sales related to cases utilizing the ClearPoint system, increased
Capital equipment and software revenue, consisting of sales of ClearPoint reusable hardware and software and related services, decreased
The Company achieved a gross margin of
Operating expenses were
Financial Results - Quarter Ended December 31, 2025
Total revenue was
Biologics and drug delivery revenue, which include sales of disposable products and services related to customer-sponsored preclinical and clinical trials utilizing our products, increased
Neurosurgery navigation and therapy revenue, which primarily consists of disposable product commercial sales related to cases utilizing the ClearPoint system, increased
Capital equipment and software revenue, consisting of sales of ClearPoint reusable hardware and software and related services, decreased
The Company achieved a gross margin of
Operating expenses were
At December 31, 2025, the Company had cash and cash equivalents totaling
Teleconference Information
Investors and analysts are invited to listen to a live broadcast review of the Company's 2025 fourth quarter and full year results on Tuesday, March 17, 2026 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here: https://event.choruscall.com/mediaframe/webcast.html?webcastid=XzyAJzOm. Investors and analysts who would like to participate in the conference call via telephone may do so at (877) 407-9034, or at (201) 493-6737 if calling from outside the U.S. or Canada.
For those who cannot access the live broadcast, a replay will be available shortly after the completion of the call until April 16, 2026, by calling (877) 660-6853 or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 413671. An online archive of the broadcast will be available on the Company's Investor website at https://ir.clearpointneuro.com/.
About ClearPoint Neuro
ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as preclinical development services for controlled drug and device delivery. The Company's flagship product, the ClearPoint Neuro Navigation System, has FDA clearance and is CE-marked. ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech companies, academic centers, and contract research organizations, providing solutions for direct central nervous system delivery of therapeutics in preclinical studies and clinical trials worldwide. To date, thousands of procedures have been performed and supported by the Company's field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com.
Forward-Looking Statements
Statements in this press release and in the teleconference referenced above concerning the Company's plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance; the market opportunity and rate of sales and revenue growth for the Company's products and services, including for the Company's preclinical CRO facility and its products and services, the Company's neuronavigational products, the IRRAflow Active Fluid Exchange System, and the PRISM Laser Therapy System; the Company's expectations for achieving key growth drivers for its sales including its ability to expand its commercial organization, receive regulatory approval for its products in new geographies, activate additional customer sites, generate clinical and economic data to support and expand the adoption rate for its products, and its development of new products; the Company's ability to successfully develop new products for gene and cell therapy delivery, including brain segmentation tools, predictive drug-delivery modeling, new pre-planning and navigation software, frame and robotic delivery options, drug loading and mechanized infusion technologies, cell and gene therapy routes-of-administration, and post procedure quality confirmation software; the adoption of the Company's products and services for use in the delivery of gene and cell therapies; the regulatory approval and commercialization of cell and gene therapies being developed by the Company's biotech Partners; and the Company's expectations for revenues, operating expenses, and management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. These forward-looking statements are based on management's current expectations and are subject to the risks inherent in the business, which may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the Company's biotech Partners' risks related to the ongoing conduct of their clinical studies, including the risk that such trials will be unable to demonstrate data sufficient to support further clinical development or regulatory approval; the risk that more patient data becomes available that results in a different interpretation then the data already released for gene and cell therapies; risks related to interactions with regulatory authorities, which may affect the initiation, timing and progress of clinical trials and pathways to regulatory approval of the biotech Partners' therapies; the limitation or modification of the FDA's eligibility and criteria for its expedited review programs with respect to such therapies; the commercialization and acceptance of gene and cell therapies; the Company's biotech Partner's continued use of the Company's products and services in their delivery of gene and cell therapies; the Company's ability to maintain its current relationships with its biotech Partners or enter into relationships with new partners; the Company's ability to continue to build and maintain the infrastructure and personnel needed to allow for widespread adoption of intracranial administration of gene and cell therapies; risks inherent in the research, development, and regulatory approval of the Company's new products; the future market for preclinical services and products and the investment required to expand such services, which could divert resources from the Company's other business operations; the possibility that the anticipated benefits of the IRRAS transaction are not realized when expected or at all; the Company's failure to integrate IRRAS into its business in accordance with expectations; deviations from the expected market potential of the IRRAS products; diversion of management's attention on the integration of IRRAS into its business; macroeconomic and inflationary conditions; regulatory and policy uncertainty; the introduction of or changes in tariffs, sanctions, or trade barriers; changes in monetary policy; geopolitical trends, such as instability, protectionism and economic nationalism; the Company's ability to market, commercialize and achieve broader market acceptance for new products and services offered by the Company; the availability of additional funding to support the Company's research and development programs and the expansion of its commercial organization; the ability of the Company to manage the growth of its business; and the Company's ability to attract and retain its key employees. For a detailed description of the Company's risks and uncertainties, you are encouraged to review its documents filed with the SEC including the Company's recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Contact:
Investor Relations:
Danilo D'Alessandro, Chief Financial Officer
(888) 287-9109 ext. 3
ir@clearpointneuro.com
CLEARPOINT NEURO, INC.
Consolidated Statements of Operations
(in thousands, except for share and per share data)
Year Ended December 31, | ||||||||
2025 | 2024 | |||||||
Revenue: | ||||||||
Product revenue | $ | 23,859 | $ | 18,626 | ||||
Service and other revenue | 13,112 | 12,764 | ||||||
Total revenue | 36,971 | 31,390 | ||||||
Cost of revenue | 14,279 | 12,268 | ||||||
Gross profit | 22,692 | 19,122 | ||||||
Research and development costs | 13,897 | 12,392 | ||||||
Sales and marketing expenses | 16,461 | 14,478 | ||||||
General and administrative expenses | 16,498 | 11,986 | ||||||
Operating loss | (24,164 | ) | (19,734 | ) | ||||
Other income (expense): | ||||||||
Other expense, net | (146 | ) | (40 | ) | ||||
Interest income | 1,213 | 1,390 | ||||||
Interest expense | (2,388 | ) | (518 | ) | ||||
Net loss before income taxes | (25,485 | ) | (18,902 | ) | ||||
Income tax expense | 55 | 12 | ||||||
Net loss | $ | (25,540 | ) | $ | (18,914 | ) | ||
Net loss per share attributable to common stockholders: | ||||||||
Basic and diluted | $ | (0.90 | ) | $ | (0.70 | ) | ||
Weighted average shares outstanding: | ||||||||
Basic and diluted | 28,315,254 | 27,027,692 | ||||||
CLEARPOINT NEURO, INC.
Consolidated Balance Sheets
(in thousands, except for share and per share data)
December 31, | ||||||||
2025 | 2024 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 45,923 | $ | 20,104 | ||||
Accounts receivable, net | 6,549 | 4,713 | ||||||
Inventory, net | 8,359 | 6,863 | ||||||
Prepaid expenses and other current assets | 2,769 | 1,683 | ||||||
Total current assets | 63,600 | 33,363 | ||||||
Property and equipment, net | 2,621 | 2,005 | ||||||
Operating lease, right-of-use assets | 8,430 | 3,086 | ||||||
Goodwill | 7,472 | - | ||||||
Intangible assets, net | 13,922 | - | ||||||
Other assets | 1,702 | 735 | ||||||
Total assets | $ | 97,747 | $ | 39,189 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 1,256 | $ | 1,340 | ||||
Accrued compensation | 4,360 | 4,885 | ||||||
Other accrued liabilities | 2,786 | 1,450 | ||||||
Operating lease liabilities, current portion | 694 | 557 | ||||||
Contract liabilities, current portion | 1,669 | 2,121 | ||||||
Total current liabilities | 10,765 | 10,353 | ||||||
Operating lease liabilities, net of current portion | 8,461 | 3,011 | ||||||
Contract liabilities, net of current portion | 581 | 436 | ||||||
Long-term notes payable, net | 49,077 | - | ||||||
Deferred tax liabilities, net | 354 | - | ||||||
Other long-term liabilities | 489 | - | ||||||
Total liabilities | 69,727 | 13,800 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity: | ||||||||
Preferred stock, | - | - | ||||||
Common stock, | 294 | 276 | ||||||
Additional paid-in capital | 238,995 | 216,483 | ||||||
Shares to be issued | 5,641 | - | ||||||
Accumulated deficit | (216,910 | ) | (191,370 | ) | ||||
Total stockholders' equity | 28,020 | 25,389 | ||||||
Total liabilities and stockholders' equity | $ | 97,747 | $ | 39,189 | ||||
CLEARPOINT NEURO, INC.
Consolidated Statements of Cash Flows
(in thousands)
Year Ended December 31, | ||||||||
2025 | 2024 | |||||||
Cash flows from operating activities: | ||||||||
Net loss | $ | (25,540 | ) | $ | (18,914 | ) | ||
Adjustments to reconcile net loss to net cash flows from operating activities: | ||||||||
Allowance for credit losses (recoveries) | 21 | (296 | ) | |||||
Depreciation and amortization | 814 | 980 | ||||||
Amortization of intangible assets | 168 | - | ||||||
Share-based compensation | 8,180 | 6,907 | ||||||
Payment-in-kind interest | 908 | - | ||||||
Amortization of debt issuance costs and original issue discounts | 83 | 51 | ||||||
Amortization of lease right of use assets, net of accretion in lease liabilities | 1,255 | 923 | ||||||
Increase (decrease) in cash resulting from changes in: | ||||||||
Accounts receivable | (268 | ) | (1,206 | ) | ||||
Inventory, net | (103 | ) | 743 | |||||
Prepaid expenses and other current assets | (397 | ) | 262 | |||||
Other assets | (195 | ) | (39 | ) | ||||
Accounts payable and accrued expenses | (7,520 | ) | 3,105 | |||||
Lease liabilities | (1,012 | ) | (869 | ) | ||||
Contract liabilities | (319 | ) | (597 | ) | ||||
Net cash flows from operating activities | (23,925 | ) | (8,950 | ) | ||||
Cash flows from investing activities: | ||||||||
Cash acquired in business combination, net of cash paid | 1,137 | - | ||||||
Purchases of property and equipment | (522 | ) | (275 | ) | ||||
Net cash flows from investing activities | 615 | (275 | ) | |||||
Cash flows from financing activities: | ||||||||
Proceeds from offerings of common stock, net of offering costs | 3,263 | 16,149 | ||||||
Proceeds from issuance of notes payable, net of financing costs and discount | 48,086 | - | ||||||
Repayment of 2020 senior secured convertible note | - | (10,000 | ) | |||||
Proceeds from stock option exercises | 127 | 21 | ||||||
Payments for taxes related to net share settlement of equity awards | (1,856 | ) | (424 | ) | ||||
Proceeds from issuance of common stock under employee stock purchase plan | 559 | 443 | ||||||
Net cash flows from financing activities | 50,179 | 6,189 | ||||||
Net change in cash, cash equivalents and restricted cash | 26,869 | (3,036 | ) | |||||
Cash, cash equivalents and restricted cash, beginning of year | 20,104 | 23,140 | ||||||
Cash, cash equivalents and restricted cash, end of year | $ | 46,973 | $ | 20,104 | ||||
Cash and cash equivalents | 45,923 | 20,104 | ||||||
Restricted cash included in other current assets and other assets, non-current | 1,050 | - | ||||||
Total cash, cash equivalents and restricted cash | $ | 46,973 | $ | 20,104 | ||||
SUPPLEMENTAL CASH FLOW INFORMATION | ||||||||
Cash paid for: | ||||||||
Income taxes | $ | 69 | $ | 62 | ||||
Interest | $ | 908 | $ | 480 | ||||
SOURCE: ClearPoint Neuro, Inc.
View the original press release on ACCESS Newswire
FAQ
What were ClearPoint Neuro (CLPT) full-year 2025 revenues and growth rates?
How did ClearPoint Neuro (CLPT) perform in Q4 2025 and what drove the increase?
What strategic acquisition did ClearPoint Neuro (CLPT) complete in 2025 and why does it matter?
What is ClearPoint Neuro's (CLPT) 2026 revenue guidance and key growth drivers?
How did ClearPoint Neuro's (CLPT) expenses and cash position change in 2025?
What regulatory and product milestones did ClearPoint Neuro (CLPT) report in 2025?
